Following the June meetings of GMMMG and CEGC, the following actions have been published to the GMMMG website. This includes the recommendations made by GMMMG in June 2025 and NICE Technology appraisals published in February 2025. A summary of approved decisions can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Updates to formulary
- Medicines for tuberculosis – restrictions placed in July 2025 (due to supply issues) removed
- Garadacimab for hereditary angioedema
- Discontinued medicines removed from formulary:
- Terbutaline 0.5mg/ml ampoules
- Bydureon BCise
- Rybelsus 3mg, 7mg & 14mg tablets
Available at https://www.greatermanchesterformulary.nhs.uk/. Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Pathways and guidelines
Updated shared care protocol:
- Atomoxetine shared care protocol for children and adolescents – https://gmmmg.nhs.uk/shared-care/gmmmg-approved-shared-care-protocols/
Colleagues are asked to disseminate for implementation within your organisations.
Items awaiting review by the ICB executive will be published once approved:
- Fenofibrate for diabetic retinopathy and diabetic maculopathy
- Fluticasone / azelastine nasal spray – generic first line, Ryaltris (mometasone / olopatadine) second line, branded Dymista non-formulary
All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.